Senolytics drug market seen reaching $2.22 billion by 2030

The Business Research Company says the senolytics drug market will climb from $1.03 billion in 2025 to $2.22 billion by 2030, driven by aging populations, regenerative medicine investment and wider clinical use. North America led the market in 2025, while Asia-Pacific is forecast to grow fastest.

Why it matters: - Senolytic drugs target senescent cells, which build up with age and contribute to chronic inflammation, tissue dysfunction and degenerative disease. - The market’s growth signals rising demand for therapies tied to healthy aging, age-related illness and regenerative medicine. - The sector could shape treatment options for conditions including fibrosis, arthritis and other chronic disorders.

What happened: - The Business Research Company projected the senolytics drug market will rise from $1.03 billion in 2025 to $1.2 billion in 2026. - The company forecast the market will reach $2.22 billion by 2030. - The report put the market’s CAGR at 16.4% for 2025-2026 and 16.7% through 2030. - The report was published Sept. 14, 2026, in London. - The company made the full senolytics drug market report available online. - The company also offered a free sample of the report.

The details: - The report said market growth has been driven by rising age-related illness, advances in cell biology related to senescence, higher investment in geroscience and early work on small molecule inhibitors that target senescent cells. - The forecast cited wider clinical adoption of senolytic treatments, growth in longevity medicine, biomarker-led therapies, more regenerative medicine funding and regulatory approvals for aging-related conditions. - The report highlighted nanoparticle-based delivery systems, repurposed oncology and metabolic drugs, and combination therapies that pair senolytic and anti-inflammatory effects as emerging trends. - The analysis expects more clinical trial networks focused on geriatric populations and evolving regulatory frameworks for aging therapeutics. - North America held the largest share of the global market in 2025. - Asia-Pacific is projected to be the fastest-growing regional market during the forecast period. - The report also covered Southeast Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report said senolytic drugs are designed to selectively remove senescent cells and support healthier aging, tissue repair and regeneration. - The report framed aging-related disease as a major driver because the global population is getting older and chronic illness is increasing with age. - The report pointed to January 2024 cardiovascular mortality data from the American Heart Association, which showed 931,578 deaths in the United States, up from 928,741 the year before.

Between the lines: - The forecast reflects a market moving from early research toward possible clinical and commercial expansion. - The emphasis on biomarkers, delivery systems and combination therapies suggests the field is still working through how to make senolytics more precise and clinically usable. - The regional split suggests the strongest near-term commercial base is in North America, while future growth may come from faster adoption elsewhere.

What's next: - The report expects more clinical adoption, more funding and more regulatory progress through 2030. - Broader proof of efficacy in aging-related conditions will likely determine how quickly senolytic therapies move from niche research into wider use. - The company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards and updated trend analysis. - The Business Research Company listed company contact and social channels for additional inquiries.